OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nguyen on the Role of Radiation Therapy in High-Risk Prostate Cancer

September 2nd 2020

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

September 2nd 2020

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Dr. Tripathy on the Evolving Treatment Landscape of HER2+ Breast Cancer

September 2nd 2020

Debu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Dr. VanderWalde on Utility of Radiation Therapy in Rectal Cancer

September 1st 2020

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Dr. Richard on the Evolving Armamentarium in Multiple Myeloma

September 1st 2020

Shambavi Richard, MD, highlights the rapidly evolving armamentarium in multiple myeloma.

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

September 1st 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

Dr. Maddocks on Emerging Therapies in Follicular Lymphoma

September 1st 2020

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

Dr. Soliman the Utility of ADCs in Breast Cancer

September 1st 2020

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Dr. Han on the Importance of Risk Stratification in HER2+ Breast Cancer

September 1st 2020

Heather S. Han, MD, discusses the importance of risk stratification in HER2-positive breast cancer.

Dr. Alkharabsheh on the Goals of Treatment in MPNs

September 1st 2020

Omar Alkharabsheh, MD, discusses the current goals of treatment in myeloproliferative neoplasms.

Dr. Roland on Findings From a Phase 2 Study With Neoadjuvant Checkpoint Blockade in Sarcoma

September 1st 2020

Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer

September 1st 2020

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML

September 1st 2020

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Dr. Flinn on the Design of a Phase 2 Trial of Zanubrutinib in CLL/SLL

August 31st 2020

Ian W. Flinn, MD, PhD, discusses the design of a phase 2 trial evaluating zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast Cancer

August 31st 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Dr. Lai on the Potential Benefits of Venetoclax in AML

August 31st 2020

Catherine Lai, MD, MPH, discusses the potential benefits of venetoclax in acute myeloid leukemia.

Dr. Sharma on the Rationale to Combine Veliparib With Chemotherapy in TNBC

August 31st 2020

Priyanka Sharma, MD, discusses the rationale to combine veliparib with chemotherapy in triple-negative breast cancer.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31st 2020

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Richter on the Utility of Isatuximab in Relapsed/Refractory Myeloma

August 31st 2020

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Dr. Dimopoulos on the Goal of the ASPEN Trial in Waldenström Macroglobulinemia

August 29th 2020

Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.